Medpace Holdings Stock Fair Value – 46K Shares Sold by 10% Owner of Medpace Holdings
December 12, 2023
☀️Trending News
Medpace Holdings ($NASDAQ:MEDP) is a clinical contract research organization (CRO) that provides personalized and integrated clinical trial services. It offers services such as global clinical trial management, protocol optimization, program optimization, and more. Recently, an owner of 10% of Medpace Holdings has sold more than 46,000 shares. This represents a significant amount of Medpace’s stock on the open market.
It is not clear at this time why the owner chose to sell such a large amount of their holdings, but it could be part of a larger financial strategy. It is important to note that this event does not necessarily reflect negatively on Medpace or its stock. In fact, it might even be a sign of confidence in the company itself.
Analysis – Medpace Holdings Stock Fair Value
At GoodWhale, we have conducted an in-depth analysis of MEDPACE HOLDINGS‘s fundamentals. Our proprietary Valuation Line has determined that the fair value of MEDPACE HOLDINGS’s share is around $278.7. Currently, the stock is trading at around $270.7, which means it is undervalued by 2.9%. This could present an interesting opportunity for potential investors to buy MEDPACE HOLDINGS’s stock at attractive prices. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Medpace Holdings. More…
| Total Revenues | Net Income | Net Margin |
| 1.78k | 273 | 15.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Medpace Holdings. More…
| Operations | Investing | Financing |
| 413.66 | -35.85 | -315.29 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Medpace Holdings. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.49k | 1.02k | 15.35 |
Key Ratios Snapshot
Some of the financial key ratios for Medpace Holdings are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 25.7% | 30.1% | 17.7% |
| FCF Margin | ROE | ROA |
| 21.2% | 45.6% | 13.2% |
Peers
Medpace’s services include clinical trial management, data management, biostatistics, and medical writing. Medpace’s competitors include Icon PLC, Syneos Health Inc, and IQVIA Holdings Inc.
– Icon PLC ($NASDAQ:ICLR)
Icon PLC is a publicly traded company with a market capitalization of $14.59 billion as of March 2022. The company has a return on equity of 4.28%. Icon is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company has a network of over 80 sites in 40 countries. Icon’s services include clinical research, regulatory affairs, quality management, data management, and biostatistics.
– Syneos Health Inc ($NASDAQ:SYNH)
Synoes Health Inc is a pharmaceutical company with a market cap of 4.81B as of 2022. The company has a Return on Equity of 9.89%. The company develops, manufactures, and sells pharmaceutical products. The company’s products include prescription drugs, over-the-counter drugs, and medical devices. The company operates in the United States, Europe, and Asia.
– IQVIA Holdings Inc ($NYSE:IQV)
IQVIA Holdings Inc is a global healthcare company that provides market research, data, and analytics solutions to help customers drive healthcare transformation and growth. The company’s market cap as of 2022 is 33.49B, and its ROE is 19.29%. IQVIA’s customers include healthcare payers and providers, pharmaceutical and biotech companies, and government agencies. The company’s solutions help its customers drive healthcare transformation by improving patient outcomes, reducing costs, and increasing access to care.
Summary
Medpace Holdings recently experienced a large sale of over 46,000 shares by a 10% owner. This is likely to cause a significant change in Medpace Holdings stock price and may be concerning for current investors. It is recommended that investors consider the reasons behind the sale before investing in Medpace Holdings. Analysts should research the company’s financials, such as revenue and net income, to assess recent performance and determine future potential of the company.
Furthermore, Medpace Holdings’ competitive landscape should be considered when making investment decisions. Finally, investors should assess the industry outlook and macroeconomic conditions to understand the potential risks and rewards of investing in Medpace Holdings.
